HK:1177 Stock Latest News
Company AnnouncementsSino Biopharm Wins Breakthrough Status for Two Hepatitis B Drugs in China5d ago
Company AnnouncementsSino Biopharm’s HER2 ADC TQB2102 Shows Strong Phase 3 Results in HER2-Low Breast Cancer6d ago
Company AnnouncementsSino Biopharm Advances First Homegrown TSLP Antibody Into Late-Stage Trials1w ago- Company AnnouncementsSino Biopharm Showcases Key Hepatitis B Drug Data at 2026 AASLD Meeting2w ago
- Company AnnouncementsSino Biopharm Completes Phase III Enrollment for Novel COPD Inhalation Drug3w ago
Company AnnouncementsSino Biopharm Strikes STADA Biosimilars Deal to Expand Global Oncology Reach1M agoCompany AnnouncementsSino Biopharm’s IL-4R Antibody for Atopic Dermatitis Clears Key Regulatory Hurdle in China1M ago
Company AnnouncementsSino Biopharmaceutical’s HER2-Low Breast Cancer ADC Wins China NDA Acceptance1M ago
Company AnnouncementsSino Biopharm Raises CT Tianqing Stake to 65% in RMB4.48 Billion Deal1M ago- Company AnnouncementsSino Biopharm Showcases Promising Oral STAT6 Degrader Data at ERS 20261M ago
Company AnnouncementsSino Biopharm’s TQC3721 COPD Inhaler Shows Strong Phase I Data1M ago- Company AnnouncementsSino Biopharm Wins FDA Green Light for Novel GPC3-Targeting Cancer ADC Trial1M ago
Company AnnouncementsSino Biopharm Strikes Exclusive HER2 ADC Deal With Cipla to Boost Emerging-Market Reach2M agoCompany AnnouncementsSino Biopharm Wins China, U.S. Green Lights for Next-Gen Nectin-4 ADC LM-3642M ago
- Company AnnouncementsSino Biopharm Wins Trial Nod for Novel Obesity Antibody TQF64222M ago
Company AnnouncementsSino Biopharmaceutical Interim Results Highlight Surge in Innovative Drug and Out-Licensing Revenue2M ago- Company AnnouncementsSino Biopharmaceutical Declares 2026 Interim Dividend of HKD 0.07 Per Share2M ago
Company AnnouncementsSino Biopharm Wins NMPA Approval for New First-Line Lung Cancer Regimen2M agoCompany AnnouncementsSino Biopharmaceutical Sets Board Meeting to Approve Interim Results and Consider Dividend2M ago
